There are currently 30 active clinical trials seeking participants for Alzheimer's Disease research studies. The states with the highest number of trials for Alzheimer's Disease participants are Florida, California, New York and Arizona.
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
NCT03019757
Recruiting
The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: The Ohio State University, Columbus, Ohio
Conditions: Alzheimer's Disease, Lewy Body Dementia, Parkinson's Disease
Register for Updates
The Feasibility, Safety and Tolerability of VR-based Audiovisual Stimulation
NCT06234930
Recruiting
This is a single-blind, sham-controlled, clinical trial that aims to evaluate the safety, tolerability, and feasibility of delivering audiovisual stimulation via a Virtual Reality (VR) headset to people cognitively impaired due to Alzheimer's and cognitively unimpaired people.
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
02/18/2025
Locations: The Sequoias Portola Valley, Portola Valley, California +1 locations
Conditions: Healthy Aging, Alzheimer's Disease
Register for Updates
Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
NCT06546995
Recruiting
This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly. Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease. Part A consists... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
02/13/2025
Locations: Neumora Investigator Site, Chandler, Arizona +17 locations
Conditions: Alzheimer's Disease, Healthy Elderly
Register for Updates
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
NCT06548191
Recruiting
The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology in patients diagnosed with Mild Cognitive Impairment (MCI) or early to moderate Alzheimer's disease (AD). It will also learn about the feasibility of practicing 14 h of nightly fasting in this group of older adults. The main questions it aims to answer are: * Does prolonged nightly fasting of 14 h can reduce markers o... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
02/10/2025
Locations: Shiley Marcos Alzheimer's Disease Center, San Diego, California
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Alzheimer's Disease
Register for Updates
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
NCT04396873
Recruiting
Background: About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation. Objective: To learn whether COX-1 and/or COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers. Eligibility: Adults age 18 years and older in good general he... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/05/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Dementia, Alzheimer's Disease, ALS, Parkinson's Disease, Mild Cognitive Impairment
Register for Updates
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357
Recruiting
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.
Gender:
ALL
Ages:
Between 60 years and 90 years
Trial Updated:
02/03/2025
Locations: JEM Research Institute, Atlantis, Florida +15 locations
Conditions: Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Register for Updates
Retinal Imaging in Neurodegenerative Disease
NCT03233646
Recruiting
This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD), or other neurodegenerative disease, diseases as outlined.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Mild Cognitive Impairment, Multiple Sclerosis, Huntington Disease, Neuro-Degenerative Disease, Alzheimer's Disease, Parkinson's Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Normal Cognition
Register for Updates
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153
Recruiting
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participat... Read More
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
01/22/2025
Locations: Parkway Medical Center, Birmingham, Alabama +336 locations
Conditions: Alzheimer's Disease
Register for Updates
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
NCT06602258
Recruiting
The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
01/20/2025
Locations: Banner Sun Health Research Institute, Sun City, Arizona +34 locations
Conditions: Alzheimer's Disease
Register for Updates
Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3
NCT06595030
Recruiting
Investigate the long-term impact of amount and duration of Tailored Lighting Intervention (TLI) obtained from Aims 1 and 2 on sleep, cognition, circadian marker, mood, and behavior in AD/ADRD patients. For this single-arm, randomized, placebo-controlled study, the researchers plan to recruit 100 participants who will experience either the active TLI or the placebo for 6 months.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
01/13/2025
Locations: Icahn School of Medicine at Mount Sinai, Menands, New York +1 locations
Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Register for Updates
A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors
NCT06411561
Recruiting
Up to 25% of intensive care unit (ICU) survivors experience cognitive impairment comparable in severity to mild Alzheimer's disease and related dementias after hospital discharge. Older ICU survivors (ages 60 and older) are at highest risk for delirium and subsequent cognitive impairment, which contribute to higher risk for cognitive decline related to Alzheimer's disease and related dementias. Sleep and activity are essential for recovery from critical illness, yet ICU survivors experience both... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
12/27/2024
Locations: University of Washington, Seattle, Washington
Conditions: Critical Illness, Delirium, Cognitive Impairment, Cognitive Decline, Alzheimer's Disease, Dementia, Circadian Dysrhythmia, Sleep Disturbance
Register for Updates
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
NCT05655195
Recruiting
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. The investigators developed a light and sound device for humans that stimulates the brain at 40Hz that can be used safely at home. For the... Read More
Gender:
ALL
Ages:
Between 65 years and 100 years
Trial Updated:
12/13/2024
Locations: Massachusetts Institute of Technology, Cambridge, Massachusetts
Conditions: Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer's Disease (Incl Subtypes), Alzheimer's, Alzheimer's Disease
Register for Updates